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Is the antiproteinuric effect of ACE inhibition mediated by interference
in the renin-angiotensin system? Angiotensin converting enzyme (ACE)
inhibition causes specific renal effects, such as a rise in effective renal
plasma flow, a fall in filtration fraction and a lowering of proteinuria.
The mechanism of these renal effects is still debated. Recent animal
studies suggest that non-angiotensin (Ang) II related actions of ACE
inhibition, such as bradykinin accumulation, may have a role. We
therefore investigated the effects of specific intervention in the renin-
angiotensin system with the Ang II receptor antagonist losartan, and
compared these effects to those obtained with ACE inhibition, as this
comparison might resolve the question whether or not the effects of
ACE inhibition are Ang II related. The effects of losartan and enalapril
were studied in eleven patients with non-diabetic proteinuria and
hypertension. The protocol consisted of seven periods, each lasting one
month, in which patients received once daily placebo, 50 mg losartan,
100mg losartan, placebo, 10mg enalapril, 20mg enalapril, and placebo,
respectively. At the end of each study period proteinuria, blood
pressure, and renal function were determined. On both doses of
losartan and enalapril proteinuria and blood pressure fell, whereas
ERPF increased and GFR remained stable. The fall in urinary protein
excretion was similar for both drugs: 46.3% (28.3% to 63.1%) on 100mg
losartan versus 51.6% (37.0% to 69.2%) on 20 mg enalapril (expressed
as Wilcoxon-based estimated median with 95% CI). The same held true
for the fall in blood pressure [15.1% (12.7% to 20.2%) vs. 17.3% (15.4%
to 22.0%)], the rise in ERPF [13.3% (4.2% to 23.4%) vs. 13.1% (4.1% to
27.0%)] and the fall in FF [15.1% (5.7% to 20.6%) vs. 14.6% (4.7% to
22.7%)]. In conclusion, the Ang II receptor antagonist losartan induces
changes in blood pressure, renal hemodynamics, and proteinuria similar
to those induced by ACE inhibition. These data support the idea that
the antiproteinuric effect of ACE inhibition, as well as the renal
hemodynamic effects, are primarily mediated by interference in the
renin-angiotensin system.
Angiotensin I converting enzyme (ACE) inhibitors show, in
addition to their antihypertensive capacity, unique renal effects,
such as a rise in effective renal plasma flow, a lowering in
filtration fraction and a decrease in urinary protein excretion
[1]. Because of these qualities, ACE inhibitors have drawn
much attention as possible renoprotective agents and as treat-
ment modality for patients with the nephrotic syndrome [1, 2].
The mechanism of these renal effects is not yet fully under-
stood. Since in experimental renal disease infusion of angioten-
sin II (Ang II) was proven to induce opposite effects, that is,
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renal vasoconstriction and an increase in proteinuria [3—6], it
was assumed that the renal effects of ACE inhibitors are the
result of inhibition of Ang II formation.
However, angiotensin I converting enzyme is identical to
kininase II, the enzyme that catabolyzes the vasodilator hor-
mone bradykinin [7]. Therefore, ACE inhibition is also hypoth-
esized to result in accumulation of bradykinin. Indeed, a
number of recent animal studies suggest that bradykinin-related
effects of ACE inhibition contribute to the renal effects [8—is].
Moreover, we recently showed in patients that Ang II infusion
did not reverse the antiproteinuric effect of long-term ACE
inhibition, despite offsetting the systemic and renal hemody-
namic effects induced by this treatment [16]. These findings
confirm the role of Ang II in the renal hemodynamic effects of
ACE inhibition; however, the role of Ang II in the antiprotein-
uric effect is clearly questioned.
Recently, an orally active nonpeptide Ang II antagonist has
been developed. This novel drug (losartan), and its active
carboxylic acid metabolite effectively block the Ang II receptor
(type 1). Both lack agonistic activity and appear to antagonize
all known physiological functions of the renin-angiotensin sys-
tem [17, 18]. Interestingly, losartan has no effect on the kinin-
kallikrein system [19]. The objectives of the present study were
first to investigate the hemodynamic and antiproteinuric effects
of specific Ang II receptor antagonism in hypertensive protein-
uric patients, and second, to compare the responses obtained
with losartan to those obtained during ACE inhibition, as this
comparison might resolve the question whether or not the
effects of ACE inhibition are Ang II related.
Methods
Patients and protocol
Patients were selected from the cohort that consecutively
attended our renal outpatient department from the starting day
of the study. Entry criteria for this study were: non-diabetic
chronic renal disease, with mild to moderate hypertension (90
mm Hg DBP  115 mm Hg), normal or mildly impaired stable
renal function (creatinine clearance  60 mi/mm), and stable
proteinuria exceeding 2.0 grams per day. Patients with diabetes,
edema, or renovascular hypertension were not allowed to
participate. Before enrollment all antihypertensive medica-
tions, including diuretics, were withdrawn for at least four
weeks. All subjects gave their informed consent for participa-
tion in this protocol, which was approved by the local Medical
Ethical Committee.
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Table 1. The effects of Ang II receptor antagonism and ACE inhibition in eleven patients
Placebo
Ang II A
50 mg 100 mg
MAP mm Hg 114.6 [108.9—120.0] 99.7 [94.6—l04.0] 95.8 [90.0_l02.0]a
GFR mI/mm 70.1 [59.5—82.3] 70.1 [60.3—81.2] 67.0 [60.6—75.5]
ERPF mI/mm 321 [289-349] 366 [326407]* 363 [334-397]
FF % 23.4 [19.0—24.5] 20.1 [17.6—21.6] 19.0 [16.9_20.4]a
Uprot glday
ACE activity U/liter 07:45
12:00
4.48 [3.33—8.84]
27.0 [22.0—35.8]
22.3 [210-295)b
3.00 [2.ll_6.85]a
29.1 [24.5—34.0]
22,8 [l9.9—25.0V'
2.43 [l.33_6.70]a
28.5 [21.3—36.0]
23.0 [20.s—31.9r'
PRA nmol/liter/hr 07:45
12:00
1.7 [0.8—3.3]
1.4 [0.8—3.2]
4.9 [2.4_8.3]a
5.8 [2.7_9,1]a
6.4 [3.8—8.6]°
9.9 [3.4—16.1]'
Ang IIpmol/liter(N 10) 07:4512:00 10.3 [6.2—13.0]7.4 [5.1—12.4] 21.8 [13.828.sr29.5 [15,7_42.9]t 25.9 [l7.933.0]°39.3 [21.053.2]a
UNa mmol/day 127 [84—181] 118 [103—143] 116 [88—154]
Uurea mmol/day 346 [298—414] 351 [315—390] 363 [327—408]
The study was performed on an ambulatory basis, and was
designed in single-blind, longitudinal order. During the study
patients adhered to a diet containing 1 g protein per kg body
weight and 100 mmol sodium per day. Patients were followed
during seven periods, each of four weeks, in which they
received once daily placebo, losartan (50 mg), losartan (100
mg), placebo, enalapril (10 mg), enalapnl (20 mg) and again
placebo, respectively. Blood pressure and urinary protein ex-
cretion (24 hr urine) were measured once weekly during the first
four periods, and at the end of the last three periods. Blood
pressure was recorded after patients had taken study medica-
tion at home. At the end of all study period patients collected
three consecutive 24-hour urines (of which the mean value is
used for data evaluation), whereafter patients were admitted for
an in-hospital renal function assessment. On these renal func-
tion study days patients took medication at 8:00 a.m., and blood
pressure was measured at 12:00 a.m. Both before (07:45 a.m.)
and after drug administration (12:00 a.m.) blood was drawn for
the determination of PRA, ACE activity and Ang II concentra-
tion. Medication compliance was assessed by tablet counts.
Patients who forgot to take study medication more than once a
week were to be excluded from analysis.
Clinical and laboratory procedures
Serum and urinary electrolytes, urea and creatinine were
determined with an automated multi-analyzer (SMA-C, Tech-
nicon®), while urinary protein was determined in each urine
sample with the pyrogallol red-molybdate method [20]. The
intra-assay coefficient of variation of this method is less than
3.3%, while the inter-assay coefficient of variation is less than
3.0%. During every visit, after at least 15 minutes of supine rest,
blood pressure was measured five consecutive times using a
Hawksley random-zero-sphygmomanometer. The first and fifth
Korotkoff sounds were used as indications for systolic and
diastolic blood pressure. The mean of three intermediate read-
ings was recorded. MAP was calculated as the sum of one-third
of the systolic and two-thirds of the diastolic blood pressure.
GFR and ERPF were measured according to a previously
described method using a constant infusion of '251-iothalamate
and '311-hippuran, respectively [21]. The intra-patient day-to-
day coefficient of variation of this method is 2.2% for GFR and
5.0% for ERPF. Both parameters were corrected for standard
body surface area (1.73 m2). Filtration fraction was calculated
as the ratio of GFR and ERPF. Serum ACE activity was
measured using a HPLC-assisted assay [22]. Plasma for the
determination of PRA and Ang II levels was drawn after 30
minutes of supine rest in prechilled tubes. Blood was immedi-
ately centrifuged at 4°C, and plasma was stored at —20°C until
analysis. PRA was assessed by the quantitation of generated
Ang I as measured by radioimmunoassay (Rianen® Ang I RIA
kit) [23]. Blood for determination of Ang II levels was collected
in tubes containing 1, lO-phenantroline, EDTA and captopril to
prevent in vitro generation or degradation of Ang H. Ang II was
determined by radioimmunoassay [24]. Cross-reactivity of the
Ang II antibody with Ang I is less than 0.1%, and 100% with
Ang III. The detection range of this assay is 2.5 to 200 fmollml
with an intra-assay coefficient of variation of 8%.
Data analysis
Data are expressed as a Wilcoxon-based estimated median,
with 95% confidence intervals (95% CI) [25], unless otherwise
indicated. Parameters are expressed as absolute value or as
percentage change from the placebo baseline value. To test for
differences between the various placebo periods a Friedmann
two-way, non-parametric ANOVA was used using baseline
placebo data as reference [26], followed by Duncan's correction
for multiple comparisons [27]. The same procedure was used to
test differences between baseline and active treatment. The
median difference in response on the Ang II antagonist and the
ACE inhibitor, both expressed as percentage change from
baseline, was estimated with a Wilcoxon-based method for
paired observations, including their 95% CI [25]. For post-hoc
analysis, the individual responses during treatment with the
Ang H antagonist were expressed as percentage of the response
obtained during ACE inhibition. The type II error (13-error) was
calculated with a Wilcoxon-based method for paired observa-
tions. Changes in hormonal parameters pre-dose versus post-
dose were tested using a Wilcoxon matched-pairs test. Statis-
tical significance was assumed at a 5% level (two-sided).
Results
Eleven patients completed the protocol. None of these had to
be excluded from analysis because of insufficient medication
compliance. Two were of female gender. All patients were
Caucasian and their median age was 42.0 years (range 20 to 61
years). All had mild to moderate hypertension [SBP 151.0 mm
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Table 1. Continued
Placebo
ACEi
Placebo10 mg 20 mg
110.2 [104. 1_i 15.7]a
71.5 [62,2—81.2]
324 [284—3473
23.1 [19.7—24.4]
4.28 [2.43—7.44]
28.0 [22.3—34.0]
24.5 [200-293]b
2.3 [1.4—3.7]
2.2 [1.4—3.4r
8.0 [5.8—9.1]
7.8 [5.5—9.5]
143 [107—1791
354 [299—410]
96.5 E91.41O3.3]a
70.4 [62.8—76.8]
363 [333396Ja
19.4 [l7.2_2l.5]a
2.49 [1.48_6.70}a
15.3 [9.3_20.8]a
4.0 [25_55]ab
6.4 [34-97]
9.7 [40-171]ab
8.6 [5.7—11.11
4.4 [2.767]b
118 [92—150]
386 [336—446]
92.9 [88.1_98.0]a
65.2 [58.9—77.0]
360 [329387r
18.8 [l6.820.7]a
2.14 [1.23_5.45]a
14.3 [7.523.8r
3.0 [25..40]ab
10.4 E6.6l4.1r
13.1 [6.6—22.Or
7.7 [5.2—10.7]
5.0 [2,9_71]th
126 [87—157]
382 [347—414]
107.3 [98.5—115.7]
70.6 [62.7—78.5]
315 [281—341]
23.3 [20.2—24.91
4.23 [2.11—7.06]
29.5 [23.0—36.1]
26.5 [21.5—31.8]
1.9 [1.2—2.7]
1.7 [1.1—2.4]
7.5 [4.2—10.5]
7.5 [4.7—10.31
131 [95—174]
354 [326—402]
Measurements were performed at the end of each one-month lasting study period. Parameters are expressed as median and 95% confidence
interval. Abbreviations are: MAP, mean arterial pressure; GFR, glomerular filtration rate; ERPF, effective renal plasma flow; FF, filtration
fraction; Uprot, proteinuria; PRA, plasma renin activity; Ang II, angiotensin II; UNa, urinary sodium excretion; Uurea, urinary urea excretion.
a p < 0.05 vs. baseline, two-way ANOVA (Friedman)bP < 0.05 vs. value obtained at 07:45 same study period, paired Wilcoxon
Fig. 1. The course of the effect (median with
95% CI) of Ang II antagonism (50 and 100 mg
losartan oid, respectively) on blood pressure
(0) and urinary protein excretion (I) in
eleven patients with non-diabetic renal
disease. Parameters are expressed as
percentage change from the mean of the four6 8 10 12 14 16 values obtained at the end of the placebo
baseline period. *jD < 0.05 vs. the mean of
Time, weeks baseline values (two-way ANOVA, Friedman)
Hg (range 139 to 180mm Hg), DBP 97.3 mm Hg (range 90 to 111
mm Hg)]. Renal function ranged from normal to mildly impaired
(creatinine clearance 94.5 mi/mm (range 60 mllmin to 114
mllmin). Patients showed nephrotic range proteinuria with a
median of 4.19 glday (range 2.2 to 14.4 g/day). Histological
diagnosis was glomeruloscierosis [5],membranous glomerulop-
athy [4], IgA nephropathy [1], and thin basement membrane
disease [1]. Most of these patients showed no signs or symp-
toms of a concomitant disease. One patient suffered from
hypothyroidism (necessitating levothyroxine treatment), an-
other suffered from asthma (necessitating treatment with saib-
utamol and ipratropium-bromide), while two had familiar hy-
perlipidemia (no treatment). Their medication was not changed
during the protocol. None of the other patients used concomi-
tant medication.
The time course of the effects of the Ang II antagonist on
blood pressure and proteinuria is shown in Figure 1. The
antihypertensive effect of the 50 mg dose showed a slow onset,
reaching a maximal effect approximately three weeks after start
of treatment. On the higher dose almost no additional effect on
blood pressure was observed. During the 50 mg dose a progres-
sive decrease in proteinuria was also observed, stabilizing
approximately three weeks after the start of treatment. When
increasing the dose to 100 mg, a further fall in proteinuria was
seen, again reaching its maximal effect after three weeks.
Table 1 and Figure 2 show the effects on blood pressure, renal
C)C
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0
0
—20
—40
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2 4
864 Gansevoort et a!: Effects of ACE inhibition and Ang II antagonism
Fig. 2. The effects (median with 95% CI) of
Ang II receptor antagonism (50 and 100 mg
oid) and ACE inhibition (10 and 20 mg oid) in
eleven patients with proteinuria due to non-
diabetic renal disease. Shaded areas represent
study periods in which active treatment (Ang
H A, angiotensin II antagonist; ACE1, ACE
inhibition) was given, while non-shaded areas
represent study periods in which placebo was
given. Changes in blood pressure (•) and
urinary protein excretion (S) are depicted in
the upper part, changes in glomerular filtration
rate (h), effective renal plasma flow (0), and
filtration fraction (0) are depicted in the lower
panel. Parameters are expressed as percentage
change from baseline. < 0.05 vs. baseline
(two-way ANOVA, Friedman)
hemodynamics and proteinuria during the two doses of both the
Ang II antagonist and the ACE inhibitor. Measurements were
performed at the end of all study periods. Blood pressure fell by
12.8% (9.6% to 16.0%) during the 50mg dose of losartan, and by
15.1% (12.7% to 20.2%) on the 100 mg dose (expressed as
Wilcoxon-based estimated median with 95% CI). During the
subsequent wash-out period blood pressure returned towards
baseline. ACE inhibition induced an antihypertensive effect of
14.9% (9.1% to 20.1%) during the 10mg dose of enalapril, and
17.3% (15.4% to 22.0%) during the 20 mg dose. The difference
in antihypertensive response obtained during the high dose of
the ACE inhibitor when compared to that on the high dose of
the Ang II antagonist was 2.3% (—2.2% to 6.6%; P 0.25).
Glomerular filtration rate remained stable during all study
periods. Effective renal plasma flow, however, rose maximally
13.3% (4.2% to 23.4%) during Ang II antagonism, and 13.1%
(4.1% to 27.0%) during ACE inhibition [difference 1.2% (—7.1%
to 8.4%), P 0.79]. As a result a fall in filtration fraction was
observed for both drugs, maximally 15.1% (5.7% to 20.6%)
during the Ang II antagonist and 14.6% (4.7% to 22.7%) during
the ACE inhibitor [difference 0.5% (—5.8% to 5.8%; P 0.86).
When measured at the end of both study periods, proteinuria
fell by 31.0% (18.6% to 41.1%) and 46.3% (28.3% to 63.1%) on
the two doses of the Ang II antagonist, respectively. These
responses were comparable with the decrease in proteinuria of
46.9% (27.4% to 57.9%) and 5 1.6% (37.0% to 69.2%) during the
two doses of the ACE inhibitor (Fig. 1). The antiproteinuric
responses during the high doses of both drugs did not differ
significantly [11.7% (—5.5% to 24.5%), P = 0.14].
Post-hoc analysis of the /3-error revealed that the probability
that the Ang II antagonist induced an effect that was 70% (or
less) of the effect obtained during ACE inhibition was 0.04 for
'I
50mg 100mg 10mg 20mg
0
20
10
0
10
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blood pressure, 0.01 for ERPF, 0.07 for FF and 0.16 for
proteinuria.
Plasma renin activity rose during Ang II antagonism both pre-
and post-dose, indicating that Ang II activity was inhibited
throughout the day (Table 1). During ACE inhibition a similar
PRA change was observed. This indicates that both drugs
induced an equivalent blockade of Ang II activity. Serum ACE
activity was stable during Ang II receptor antagonism, and
decreased during ACE inhibition, as expected. During Ang II
antagonism the plasma concentration of Ang II increased, while
during ACE inhibition a decrease in the effector hormone of the
renin-angiotensin system was observed post-dose.
Patients, in general complied well with the instituted dietary
restrictions, reflected by the stable median urinary sodium and
urea excretion. Both the ACE inhibitor and the novel Ang II
antagonist were well tolerated, as patients did not complain
about side-effects while on either drug.
Discussion
In the present study we found the Ang II antagonist losartan
to induce a fall in blood pressure, a rise in effective renal plasma
flow, a lowering of the filtration fraction, and particularly to
induce a decrease in urinary protein excretion. Interestingly,
these changes were both qualitatively and quantitatively similar
to those observed with the ACE inhibitor enalapril.
Our study is the first to investigate the effects of an Ang II
receptor antagonist in patients with renal disease. The antihy-
pertensive effect compares well to that found in patients with
essential hypertension [28]. Data on renal hemodynamics and
proteinuria have not been published previously in any patient
category. Our finding of a stable GFR with a concomitant
increase in ERPF is compatible with renal vasodilation. The
reduction in proteinuria may be the result of a fall in intraglom-
erular pressure and/or changes in glomerular basement mem-
brane characteristics. This systemic and renal profile closely
resembles that of ACE inhibitors, which are known for their
blood pressure lowering efficacy, renal vasodilation and anti-
proteinuric effect. This could well suggest that both drugs have
a similar mode of action. Before drawing this conclusion one,
however, has to consider the possible limitations of our study:
drug choice, dose choice and the longitudinal design.
With regard to the choice of enalapril, two recent meta-
analyses did not provide clues that one ACE inhibitor would be
superior to another as far as hemodynamic or antiproteinuric
effects are concerned [29, 30]. It is therefore unlikely that we
would have obtained different results in this comparison trial
using another ACE inhibitor. The choice of losartan was
dictated, as only one Ang II antagonist is available for clinical
purposes. However, losartan appears to be very specific in
blocking only the type 1 Ang II receptor, without interfering in
other hormonal systems [19]. These premises allow us, within
the objective of our study, to draw conclusions on the role of
the angiotensin system in the antiproteinuric effect of ACE
inhibitors.
When comparing the efficacy of two drugs, this should be
done with a dose of either drug that induces the maximal effect.
As far as this is concerned, a comparison appears justified since
both drugs were at near maximal dose. Indeed, blood pressure,
renal hemodynamic parameters, and to a lesser extent also
proteinuria, showed only a modest response to doubling of the
dose of both the Ang II antagonist and ACE inhibition. More-
over, the effects of both drugs closely mimic the maximal
effects described in literature [1, 28, 31].
The study should, of course, ideally have been performed
according to a randomized, placebo-controlled, crossover de-
sign. Limited clinical experience, however, forced us to per-
form this phase II study as a single-blind longitudinal one. This
design might have caused carry-over effects, though a distinct
impact of this bias on the conclusion drawn seems rather
unlikely. First, both active treatment modalities were separated
by a four-week placebo period. Moreover, the effects of the
ACE inhibitor used for comparison were obtained 12 weeks
after withdrawal of the Ang II antagonist. It is hard to imagine
that the former drug will have interfered with the latter. This
consideration is strengthened by the observation of a near
complete recovery of the principal parameters in the placebo
wash-out and recovery periods. Second, even when carryover
effects, or the course of the underlying disease are in play, this
can only have worked to the disadvantage of the conclusion
drawn. The ACE inhibitor-induced effects are related to the first
placebo period (pre-losartan). Since proteinuria and blood
pressure did not reach baseline completely in the intermediate
placebo period, this may only have exaggerated the effects of
the ACE inhibitor. When the response on both drugs is ex-
pressed as change compared to the respective preceding pla-
cebo periods, most parameters change even less during ACE
inhibition than during Ang II antagonism. Thus, we may con-
clude that Ang II antagonism induced similar effects as ACE
inhibition on the studied parameters.
What are the consequences of our observation that the Ang II
antagonist and the ACE inhibitor induce similar effects? First of
all, it indicates that the Ang II antagonist may be of similar
clinical value as ACE inhibitors in treating patients with hyper-
tension or the nephrotic syndrome. Both drugs appear to lower
blood pressure adequately, while inducing a renal vasodilation
and a decrease of urinary protein excretion. This profile has
been hypothesized to be protective against progression of renal
function decline.
Second, the strikingly similar response to Ang II antagonism
and ACE inhibition has interesting renal physiological implica-
tions, as it suggests that the ACE inhibitor-induced effects are
indeed caused by inhibition of Ang II activity, and not so much
by interference in the kinin-kallikrein system as has been
suggested so often by various experimental animal studies
[8—15]. Although species differences seem a logical explanation
for these conflicting results, differences in design of animal
studies also have to be considered, since several other animal
studies found Ang II antagonism and ACE inhibition to be
equally effective in renal protection [32—35]. The present find-
ings may seem contradictory to the above-mentioned observa-
tion of Heeg et al [16], who found that acute angiotensin II
infusion could not offset the antiproteinuric effect of chronic
ACE inhibition, though restoring the systemic and renal hemo-
dynamic effects to control values. While that study questions a
role of angiotensin II in the antiproteinuric effect of ACE
inhibition, the present study indicates that blockade of angio-
tensin II activity is pivotal. A possible explanation for this
discrepancy may be that infusion of Ang II is not the correct
way of substituting the endogenous Ang II that has been
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diminished by ACE inhibition, since the exogenous adminis-
tered hormone may not reach all "Ang II deprived" effector
sites. Alternatively, an explanation can be found in the different
time scales in both studies. Ang II infusion was only continued
for hours, whereas ACE inhibition and Ang II antagonist
therapy lasted for weeks. Intriguingly, we recently demon-
strated that the antiproteinuric effect of ACE inhibition has a
slow onset, reaching its maximal effect only several weeks after
the start of treatment [36]. Thus, the fact that Ang II infusion
does not offset the antiproteinuric effect of ACE inhibition may
be due to too short an infusion time. In this context it is
important to note that the antiproteinuric effect of losartan
showed a similar slow onset, reaching its maximum only three
weeks after start of treatment. This observation demonstrates
that the effects of Ang II antagonism should be assessed only
several weeks after start of treatment, both in clinical practice
and in future studies.
In conclusion, in patients with renal disease, the Ang II
receptor antagonist losartan reduces blood pressure, filtration
fraction, and proteinuria. These effects were similar to those
obtained with the ACE inhibitor enalapril. The present data
support the idea that the beneficial renal effects specific for
ACE inhibitors are primarily mediated by interference in the
renin-angiotensin system. Whether Ang H antagonists, by
means of their greater specificity, will prove to be drugs of
choice for the future has yet to be disclosed in large compara-
tive trials.
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